SEARCH

SEARCH BY CITATION

References

  • 1
    Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 14001411.
  • 2
    Harrison TS, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 17151736.
  • 3
    Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. Eur. Psychiatry 2007; 22: 433443.
  • 4
    Hanssens L, L'Italien G, Loze JY et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008; 8: 95.
  • 5
    Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications. Occupancy is not just antagonism. Arch. Gen. Psychiatry 2003; 60: 974977.
  • 6
    Mihara K, Nagai G, Nakamura A et al. Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients. Clin. Neuropharmacol. Ther. 2010; 1: 15.
  • 7
    Yasui-Furukori N, Saito M, Nakagami T et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2010; 34: 537540.
  • 8
    Yasui N, Kondo T, Otani K et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol. Toxicol. 1998; 82: 153156.
  • 9
    Yasui-Furukori N, Kondo T, Suzuki A et al. Effects of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. Schizophr. Res. 2001; 52: 139142.
  • 10
    Jönsson EG, Nöthen MM, Grünhage F et al. Polymorphism in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999; 4: 290296.
  • 11
    Mihara K, Kondo T, Suzuki A et al. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology 2000; 149: 246250.
  • 12
    Mihara K, Suzuki A, Kondo T et al. Relationship between Taq1 A dopamine receptor (DRD2) polymorphism and prolactin response to bromperidol. Am. J. Med. Genet. 2001; 105: 271274.
  • 13
    Young RM, Lawford BR, Barnes M et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br. J. Psychiatry 2004; 185: 147151.
  • 14
    Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet. Genomics 2007; 17: 989993.
  • 15
    Calarge CA, Ellingrod VL, Acion L et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet. Genomics 2009; 19: 373382.
  • 16
    Zhang XR, Zhang ZJ, Zhu RX, Yuan YG, Jenkins TA, Reynolds GP. Sexual dysfunction in male schizophrenia: Influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 2011; 12: 11271136.
  • 17
    Sakuyama K, Sasaki T, Ujiie S et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos. 2008; 36: 24602467.
  • 18
    Ozdemir V, Bertilsson L, Miura J et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revised. Pharmacogenet. Genomics 2007; 17: 339347.
  • 19
    Kubo M, Koue T, Maune H, Fukuda T, Azuma J. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: Influence of CYP2D6 polymorphism. Drug Metab. Pharmacokinet. 2007; 22: 358366.
  • 20
    Kubo M, Mizooku Y, Hirao Y, Osumi T. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J. Chromatogr. B 2005; 822: 294299.
  • 21
    Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum. Mol. Genet. 1993; 2: 2197.
  • 22
    Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 1997; 41: 577582.
  • 23
    Steen VM, Andreassen OA, Daly AK et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215223.
  • 24
    Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 2000; 50: 3134.
  • 25
    Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 1994; 46: 452459.
  • 26
    Kirschbaum KM, Müller MJ, Malevani J et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J. Biol. Psychiatry 2008; 9: 212218.
  • 27
    Gründer G, Fellows C, Janouschek H et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F] fallypride PET study. Am. J. Psychiatry 2008; 165: 988995.
  • 28
    Suzuki T, Mihara K, Nakamura A et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther. Drug Monit. 2011; 33: 2124.
  • 29
    Kwon JS, Kim E, Kang DH et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur. Neuropsychopharmacol. 2008; 18: 897907.
  • 30
    Iranmanesh A, Mulligan T, Veldhuis JD. Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: Dual decline in prolactin secretary burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval- a General Clinical Research Center study. J. Clin. Endocrinol. Metab. 1999; 85: 10831090.
  • 31
    Ufearo CS, Orisakwe OE. Restoration of normal sperm characteristics in hypoprolactinemia infertile men treated with metoclopramide and exogenous human prolactin. Clin. Pharmacol. Ther. 1995; 58: 354359.
  • 32
    Houston J, Dharia S, Bishop JR et al. Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res. 2011; 187: 7479.